Wedbush Reiterates Underperform Rating for ImageneBio (NASDAQ:IMA)

Posted by on May 11th, 2026

ImageneBio (NASDAQ:IMA – Get Free Report)‘s stock had its “underperform” rating restated by analysts at Wedbush in a research note issued on Monday,Benzinga reports. They presently have a $2.00 price target on the stock. Wedbush’s target price points to a potential downside of 62.19% from the company’s current price.

Separately, Wall Street Zen lowered ImageneBio from a “hold” rating to a “sell” rating in a research report on Saturday. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $16.00.

Get Our Latest Analysis on IMA

ImageneBio Stock Performance

Shares of IMA opened at $5.29 on Monday. The firm has a market capitalization of $56.34 million, a price-to-earnings ratio of -0.91 and a beta of 0.73. The business’s fifty day moving average price is $5.71 and its two-hundred day moving average price is $6.60. ImageneBio has a 52 week low of $3.94 and a 52 week high of $18.00.

ImageneBio (NASDAQ:IMA – Get Free Report) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.95) EPS for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.25). As a group, research analysts forecast that ImageneBio will post -2.98 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Barclays PLC lifted its stake in shares of ImageneBio by 170.8% in the 4th quarter. Barclays PLC now owns 10,797 shares of the company’s stock valued at $74,000 after purchasing an additional 6,810 shares during the period. Goldman Sachs Group Inc. acquired a new position in shares of ImageneBio in the 4th quarter valued at $76,000. Millennium Management LLC acquired a new position in shares of ImageneBio in the 4th quarter valued at $79,000. T3 Companies LLC acquired a new position in shares of ImageneBio in the 4th quarter valued at $91,000. Finally, Jane Street Group LLC acquired a new position in shares of ImageneBio in the 4th quarter valued at $103,000. Institutional investors and hedge funds own 75.00% of the company’s stock.

About ImageneBio

(Get Free Report)

ImageneBio, Inc, a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc and changed its name to ImageneBio, Inc in July 2025. ImageneBio, Inc is headquartered in San Diego, California.

Featured Stories

Receive News & Ratings for ImageneBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImageneBio and related companies with MarketBeat.com's FREE daily email newsletter.